Novavax triumphs on US stock exchange despite lack of FDA approval
![Photo: Dado Ruvic/REUTERS / X02714](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14122327.ece/ALTERNATES/schema-16_9/doc7ld5qjz1kqhm8g55m87.jpg)
On Thursday, shares in Novavax increased by 13.5% in value, while its larger competitor Moderna reached the upper echelons of the S&P 500 index after a 7.9% value increase.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novavax vaccine recommended for approval for EU teenagers
For subscribers
Regulators agree on Covid-19 vaccination adaptation plan
For subscribers
Moderna on booster race: May the best data win
For subscribers